Maryland SB527 establishes a grant program for clinical research on ibogaine for opioid use disorder and neurological conditions.

Maryland SB527 creates the Ibogaine Clinical Research Grant Program, which provides grants to eligible research institutions for clinical drug development trials on ibogaine. The program aims to explore ibogaine's efficacy in treating opioid use disorder and other neurological conditions. The Department of Health will administer the program, awarding up to three grants annually, with recipients required to submit quarterly progress and financial reports. The program is funded by the Opioid Restitution Fund, with annual appropriations of $500,000 from fiscal years 2028 through 2030.

Maryland SB527 establishes a grant program for clinical research on ibogaine for opioid use disorder and neurological conditions.

Maryland SB527 creates the Ibogaine Clinical Research Grant Program, which provides grants to eligible research institutions for clinical drug development trials on ibogaine. The program aims to explore ibogaine's efficacy in treating opioid use disorder and other neurological conditions. The Department of Health will administer the program, awarding up to three grants annually, with recipients required to submit quarterly progress and financial reports. The program is funded by the Opioid Restitution Fund, with annual appropriations of $500,000 from fiscal years 2028 through 2030.